Show simple item record

dc.contributor.authorLonial, Sagar
dc.contributor.authorNooka, Ajay K
dc.contributor.authorThulasi, Praneetha
dc.contributor.authorBadros, Ashraf Z
dc.contributor.authorJeng, Bennie H
dc.contributor.authorCallander, Natalie S
dc.contributor.authorPotter, Heather A
dc.contributor.authorSborov, Douglas
dc.contributor.authorZaugg, Brian E
dc.contributor.authorPopat, Rakesh
dc.contributor.authorDegli Esposti, Simona
dc.contributor.authorByrne, Julie
dc.contributor.authorOpalinska, Joanna
dc.contributor.authorBaron, January
dc.contributor.authorPiontek, Trisha
dc.contributor.authorGupta, Ira
dc.contributor.authorDana, Reza
dc.contributor.authorFarooq, Asim V
dc.contributor.authorColby, Kathryn
dc.contributor.authorJakubowiak, Andrzej
dc.date.accessioned2021-06-03T13:53:05Z
dc.date.available2021-06-03T13:53:05Z
dc.date.issued2021-05-26
dc.identifier.urihttp://hdl.handle.net/10713/15911
dc.description.abstractBelantamab mafodotin (belamaf) demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM) in DREAMM-2 (NCT03525678). Corneal events, specifically keratopathy (including superficial punctate keratopathy and/or microcyst-like epithelial changes (MECs), eye examination findings with/without symptoms), were common, consistent with reports from other antibody-drug conjugates. Given the novel nature of corneal events in RRMM management, guidelines are required for their prompt identification and appropriate management. Eye examination findings from DREAMM-2 and insights from hematology/oncology investigators and ophthalmologists, including corneal specialists, were collated and used to develop corneal event management guidelines. The following recommendations were formulated: close collaboration among hematologist/oncologists and eye care professionals is needed, in part, to provide optimal care in relation to the belamaf benefit-risk profile. Patients receiving belamaf should undergo eye examinations before and during every treatment cycle and promptly upon worsening of symptoms. Severity of corneal events should be determined based on corneal examination findings and changes in best-corrected visual acuity. Treatment decisions, including dose modifications, should be based on the most severe finding present. These guidelines are recommended for the assessment and management of belamaf-associated ocular events to help mitigate ocular risk and enable patients to continue to experience a clinical benefit with belamaf.en_US
dc.description.urihttps://doi.org/10.1038/s41408-021-00494-4en_US
dc.language.isoenen_US
dc.publisherSpringer Natureen_US
dc.relation.ispartofBlood Cancer Journalen_US
dc.subjectbelantamab mafodotinen_US
dc.subjectDREAMM-2en_US
dc.subject.meshCorneaen_US
dc.subject.meshImmunoconjugates--adverse effectsen_US
dc.subject.meshMultiple Myelomaen_US
dc.titleManagement of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)en_US
dc.typeArticleen_US
dc.identifier.doi10.1038/s41408-021-00494-4
dc.identifier.pmid34039952
dc.source.volume11
dc.source.issue5
dc.source.beginpage103
dc.source.endpage
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record